Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus price target of $12.25 for the company and are predicting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also given Brainstorm Cell Therapeutics an industry rank of 64 out of 256 based on the ratings given to related companies.
Separately, Maxim Group reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Brainstorm Cell Therapeutics in a research note on Tuesday, January 22nd.
An institutional investor recently raised its position in Brainstorm Cell Therapeutics stock. ETF Managers Group LLC increased its stake in shares of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) by 75.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,797 shares of the biotechnology company’s stock after purchasing an additional 28,809 shares during the quarter. ETF Managers Group LLC owned 0.32% of Brainstorm Cell Therapeutics worth $237,000 at the end of the most recent quarter. 8.30% of the stock is owned by institutional investors.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Read More: What is the Stochastic Momentum Index (SMI)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.